Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06126653 · ClinicalTrials.gov registry record · Phase 2
A Study to Evaluate ARD-501 in Patients With Autism Spectrum Disorder
A Phase 2 study of Autism Spectrum Disorder, sponsored by Aardvark Therapeutics.
- Completed
- Registry status
- Phase 2
- Development phase
- 5
- Enrollment target
- 1
- Study location
NCT06126653: Completed Phase 2 study of Autism Spectrum Disorder, sponsored by Aardvark Therapeutics.
NCT06126653 is a Phase 2 study of Autism Spectrum Disorder that has completed, run by Aardvark Therapeutics. The registered enrollment target is 5 participants, below the 135-participant average among 224 other Autism Spectrum Disorder trials with a reported enrollment target (96% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06126653, a Phase 2 study of Autism Spectrum Disorder, has completed, sponsored by Aardvark Therapeutics.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 5 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a blinded, placebo controlled, cross-over trial evaluating the safety of two dose-levels of ARD-501 in subjects with ASD.
Primary Outcome
To measure the efficacy evaluation of safety in subjects with autism spectrum disorder (ASD) by assessment of the incidence of Treatment-Emergent Adverse Events (TEAE).
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Low Dose ARD-501
- DRUG High Dose ARD-501
Study Locations (1)
Nevada
- Center for Psychiatry and Behavioral Medicine Inc - Las Vegas
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 5 participants |
| Start Date | 2024-08-01 |
| Est. Completion | 2025-01-13 |
| Phase | Phase 2 |
What the finished NCT06126653 record still lists
NCT06126653 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 5 participants, a relatively small participant target, below the 135-participant average among 224 other Autism Spectrum Disorder trials with a reported enrollment target (96% lower).
The record links to 1 condition, with Autism Spectrum Disorder appearing as the primary indexed condition, and to 3 interventions - of which Placebo is the first listed.
NCT06126653 reports a single indexed study location in Nevada.
Frequently Asked Questions
What is clinical trial NCT06126653 about?
NCT06126653 is a clinical study titled "A Study to Evaluate ARD-501 in Patients With Autism Spectrum Disorder". This is a blinded, placebo controlled, cross-over trial evaluating the safety of two dose-levels of ARD-501 in subjects with ASD.
What is the current status of trial NCT06126653?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 5 participants. The study started on 2024-08-01. Estimated completion is 2025-01-13.
What conditions does trial NCT06126653 study?
This clinical trial studies the following conditions: Autism Spectrum Disorder.
What interventions are being tested in trial NCT06126653?
The interventions under investigation include: Placebo (DRUG), Low Dose ARD-501 (DRUG), High Dose ARD-501 (DRUG).
Who is sponsoring clinical trial NCT06126653?
This trial is sponsored by Aardvark Therapeutics, which has 6 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06126653 being conducted?
This trial has 1 study location across Nevada. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Autism Spectrum Disorder
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06126653's enrollment target sits among peer trials
5 225th of 224 the lowest of 224 other Autism Spectrum Disorder trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Autism Spectrum Disorder trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Pimavanserin for Rigid-compulsive Symptoms in Autism Spectrum Disorder
RECRUITING · Phase 2
-
Targeting the Neurobiology of RRB in Autism Using N-acetylcysteine: Trial
RECRUITING · Phase 2
-
Early Treatment of Language Impairment in Young Children With Autism Spectrum Disorder With Leucovorin Calcium
RECRUITING · Phase 2
-
Optimizing Outcomes for Young Autistic Children
RECRUITING · Phase 2
-
Trial of Zolpidem for Sleep in Children With Autism
RECRUITING · Phase 2
-
Telehealth-Enabled Versus In-Person Parent-Mediated Behavioral Treatment for Challenging Behaviors in Children With ASD
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI